At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed metastatic/unresectable melanoma (phase II) or metastatic/unresectable malignancy without effective standard measures (phase I)
- ✓ECOG performance status 0-1
- ✓Measurable disease (phase II only)
- ✓WBC ≥3,000/mm³, ANC ≥1,500/mm³, platelets ≥100,000/mm³
- ✕History or clinical evidence of CNS disease including primary brain tumor or brain metastases
- ✕Significant cardiovascular disease within past 6 months: MI, unstable angina, NYHA class II-IV CHF, serious cardiac arrhythmia, grade II+ peripheral vascular disease, TIA, stroke, arterial thromboembolism
- ✕Seizures not controlled with standard medical therapy
- ✕Prior allergic reactions to Chinese hamster ovary cell products, recombinant human antibodies, or compounds similar to imatinib mesylate
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study Of Imatinib Mesylate And Bevacizumab In Patients With Advanced Melanoma And Other Advanced Cancers
In Brief
A Phase 2 clinical trial evaluating imatinib mesylate, bevacizumab, and 2 other interventions for Recurrent Melanoma and 3 related conditions. Completed, enrolled 40 participants across 1 site.
Detailed Summary
Phase II trial to study the effectiveness of combining imatinib mesylate with bevacizumab in treating patients who have advanced melanoma or other metastatic or unresectable cancer. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Bevacizumab may stop the growth of tumor cells by stopping blood flow to the tumor. Combining imatinib mesylate with bevacizumab may kill more tumor cells
Study Details
Timeline
Interventions
Given orally
Given IV
Correlative studies
Correlative studies